Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in recurrent or metastatic primary malignant bone tumors
CTR20181003Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of catequentinib in osteosarcoma (OS), chondrosarcoma, Malignant Fibrous Histiocytoma of Bone (MFH), Giant Cell Tumor of Bone (GCTB), Ewing sarcoma of bone, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2018; status: active.
02
Drugs
catequentinib
03
Conditions
osteosarcoma (OS)chondrosarcomaMalignant Fibrous Histiocytoma of Bone (MFH)Giant Cell Tumor of Bone (GCTB)Ewing sarcoma of bone
Beyond the preview
Go deeper on CTR20181003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181003.